Sutter Health Research Enterprise
11795 Education Street
Suite 232
Auburn, CA, 95602
(888) 729-3488
kimbk@sutterhealth.org
Related Clinical Trials
Adjuvant Breast (EndoPredict Extended Endocrine Trial EXET Myriad)
To evaluate the impact of using EndoPredict clinically to inform treatment decisions
for extended endocrine therapy and the subsequent impact on patient outcome
Investigators: Kristin N. Arreola M.D., Kristie A. Bobolis M.D., Rajeswari Chellappah M.D., Jaspreet K Dhillon Medical Oncologist, Brian K. Kim M.D, Sivakumar Reddy M.D., Nitin Rohatgi MD, Vijay Suhag M.D.
Status: Active, Recruiting
City of Hope 96144 Molecular Genetics Studies of Cancer Patients and Their Relatives
The purpose of this study is to find out how genetics, biologics and behavior might
contribute to
Investigators: Kristin N. Arreola M.D., Kristie A. Bobolis M.D., Rajeswari Chellappah M.D., Brian K. Kim M.D, Sivakumar Reddy M.D., Vijay Suhag M.D.
Status: Active, Recruiting
Imaging of T-cell Activation With [18F]F-AraG in Advanced NSCLC
Pilot study using [18F]F AraG PET imaging to evaluate the immunological response to
checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC
Investigators: Deepti Behl MD, Brian K. Kim M.D, Vijay Suhag M.D.
Status: Active, Recruiting
Locally Advanced (TIGeR-PaC Study)
Multi-center, un-blinded, randomized control study of subjects with locally advanced
pancreatic adenocarcinoma which is unresectable.
Investigators: Deepti Behl MD, Brian K. Kim M.D, Christopher J Laing M.D., Sivakumar Reddy M.D., Vijay Suhag M.D.
Status: Active, Recruiting
Locally Advanced (ZEAL-1L GlaxoSmithKline 213400)
Multicenter, randomized, double-blind, placebo-controlled study of niraparib plus
pembrolizumab versus placebo plus pembrolizumab as maintenance therapy
Investigators: Kristin N. Arreola M.D., Deepti Behl MD, Kristie A. Bobolis M.D., Rajeswari Chellappah M.D., Jaspreet K Dhillon Medical Oncologist, Brian K. Kim M.D, Sivakumar Reddy M.D., Vijay Suhag M.D.
Status: Active, Recruiting
Napoli 3-Ipsen (D-US-60010-001)
Randomized, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin,
5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine
Investigators: Kristin N. Arreola M.D., Deepti Behl MD, Brian K. Kim M.D, Jasdeepa Nagi M.D., Sivakumar Reddy M.D.
Status: Active, Recruiting
RESILIENT-Ipsen (MM-398-01-03-04)
A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection vs Toptecan
in patients with SCLC
Investigators: Kristin N. Arreola M.D., Deepti Behl MD, Rajeswari Chellappah M.D., Brian K. Kim M.D, Jasdeepa Nagi M.D., Sivakumar Reddy M.D., Nitin Rohatgi MD, Vijay Suhag M.D.
Status: Active, Not Recruiting
Research Studies
Genomic Health Oncotype DX AR-V7
Genomic Health 09-060
Investigators: Kristin N. Arreola M.D., Kristie A. Bobolis M.D., Rajeswari Chellappah M.D., Brian K. Kim M.D, Sivakumar Reddy M.D., Nitin Rohatgi MD, Vijay Suhag M.D., David S Yee M.D., MPH